Notably, NEMO-IKK complex promoted the activation of canonical NF-κB pathway in AML [21], thus suggesting that the use of NEMO-binding domain peptides could represent an alternative strategy to indirectly inhibit NF-κB in this cancer. This evidence concerns the gene NFKB1 and cancer.